<DOC>
	<DOC>NCT00853840</DOC>
	<brief_summary>The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in subjects receiving a single dose of vardenafil.</brief_summary>
	<brief_title>Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc</brief_title>
	<detailed_description />
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male subjects. no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead electrocardiogram and clinical laboratory tests. Body mass index (BMI) of approximately 18 to 30 kg/m2; and a total body weight &gt;50 kg (110 lbs). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Subjects with a supine systolic BP of greater than 140 mm Hg, or a supine diastolic BP of greater than 90 mm Hg, either at Screening or at the predose measurements.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>pharmacodynamics. maraviroc, vardenafil, blood pressure</keyword>
</DOC>